Home > Search Results: Dalmau, Judith
  Search Tips
Advanced Search
Search collections:
Sort by: Display results: Output format:
Results overview: Found 4 records in 0.02 seconds.
Articles, 3 records found
Research literature, 1 records found
Articles 3 records found  
1.
11 p, 679.0 KB Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4 + T-cell recovery once HIV-1 suppression is achieved? / Jarrin, Inma (Instituto de Salud Carlos III, Madrid, Spain) ; Pantazis, Nikos (Athens University Medical School, Athens, Greece) ; Dalmau, Judith (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Phillips, Andrew N. (Research Department of Infection and Population Health) ; Olson, Ashley (Medical Research Council Clinical Trials Unit, University College London, London, UK) ; Mussini, Cristina (Institute of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy) ; Boufassa, Faroudy (Univ Paris-Sud, Le Kremlim Bicetre) ; Costagliola, Dominique (INSERM, Paris, France) ; Porter, Kholoud (Medical Research Council Clinical Trials Unit, University College London, London, UK) ; Blanco, Juliá (Universitat de Vic-Central de Catalunya, UVIC-UCC, Vic) ; Del Amo, Julia (Instituto de Salud Carlos III, Madrid, Spain) ; Martínez Picado, Francisco Javier (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
This article compares trends in CD4 + T-cell recovery and proportions achieving optimal restoration (≥500 cells/μl) after viral suppression following combination antiretroviral therapy (cART) initiation between rapid and nonrapid progressors. [...]
2015 - 10.1097/QAD.0000000000000805
AIDS (London, England), Vol. 29 (october 2015) , p. 2323-2333  
Detailed record - Creative Commons
2.
7 p, 617.5 KB Identification of Siglec-1 null individuals infected with HIV-1 / Martínez Picado, Francisco Javier (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; McLaren, Paul J. (National HIV and Retrovirology Laboratory (Winnipeg, Canadà)) ; Erkizia, Itziar (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Martin, Maureen P. (Frederick National Laboratory for Cancer Research (Maryland, Estats Units d'Amèrica)) ; Benet, Susana (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Rotger, Margalida (University of Lausanne (Suïssa)) ; Dalmau, Judith (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Ouchi, Dan (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Wolinsky, Steven M. (Northwestern University Feinberg School of Medicine (Chicago, Estats Units d'Amèrica)) ; Penugonda, Sudhir (Northwestern University Feinberg School of Medicine (Chicago, Estats Units d'Amèrica)) ; Günthard, Huldrych F. (University Hospital Zurich (Suïssa)) ; Fellay, Jacques (École Polytechnique Fédérale de Lausanne (Suïssa)) ; Carrington, Mary (Frederick National Laboratory for Cancer Research (Maryland, Estats Units d'Amèrica)) ; Izquierdo Useros, Nuria (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Telenti, Amalio (J. Craig Venter Institute (La Jolla, Estats Units d'Amèrica))
Siglec-1/CD169 is a myeloid-cell surface receptor critical for HIV-1 capture and infection of bystander target cells. To dissect the role of SIGLEC1 in natura, we scan a large population genetic database and identify a loss-of-function variant (Glu88Ter) that is found in ∼1% of healthy people. [...]
2016 - 10.1038/ncomms12412
Nature communications, Vol. 7 Núm. 12412 (August 2016)  
Detailed record - Creative Commons
3.
15 p, 3.1 MB HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells / Pino, Maria (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Erkizia, Itziar (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Benet, Susana (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Erikson, Elina (University of Frankfurt (Alemanya)) ; Fernández Figueras, Maria Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Guerrero, Dolores (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Dalmau, Judith (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Ouchi, Dan (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Rausell, Antonio (University of Lausanne (Suïssa)) ; Ciuffi, Angela (University of Lausanne (Suïssa)) ; Keppler, Oliver T. (University of Frankfurt (Alemanya)) ; Telenti, Amalio (University of Lausanne (Suïssa)) ; Kräusslich, Hans-Georg (University of Heidelberg (Alemanya)) ; Martínez Picado, Francisco Javier (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Izquierdo Useros, Nuria (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Universitat Autònoma de Barcelona
Myeloid cells are key players in the recognition and response of the host against invading viruses. Paradoxically, upon HIV-1 infection, myeloid cells might also promote viral pathogenesis through trans-infection, a mechanism that promotes HIV-1 transmission to target cells via viral capture and storage. [...]
2015 - 10.1186/s12977-015-0160-x
Retrovirology, Vol 12, article 37 (May 2015)  
Detailed record - Creative Commons

Research literature 1 records found  
1.
281 p, 4.1 MB Viral and host factors involved in rapid HIV-1 disease progression / Dalmau Moreno, Judith ; Martínez Picado, Francisco Javier, dir. ; Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular
Els éssers humans mostren una notable variació en el desenvolupament clínic rere la infecció per VIH-1. Si bé algunes persones amb VIH-1 són capaces de suprimir la replicació viral del VIH a nivells molt baixos ( 2000 còpies/ml) i/o mantenir els recomptes de CD4 alts durant molts anys en absència de teràpia antiretroviral (Controladors), altres progressen ràpidament a sida o compleixen els criteris actuals per a iniciar tractament antiretroviral en els 3 primers anys rere la infecció primària (Progressors ràpids, RP). [...]
Remarkable variation in clinical outcome can be observed following HIV-1 infection. While some HIV-1–infected individuals are able to suppress viral replication to very low levels ( 2000 copies/mL) and/or maintain high CD4+ T-cell counts over many years without antiretroviral therapy (HIV controllers), others quickly progress to AIDS or meet the current criteria for antiretroviral treatment within the first 3 years after primary infection (rapid progressors, RP). [...]
[Barcelona] : Universitat Autònoma de Barcelona, 2014  
Detailed record -

See also: similar author names
1 Dalmau, Jaime
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.
UAB Digital Repository of Documents :: Search :: Submit :: Personalize :: Help
Powered by Invenio v1.1.6
Maintained by ddd.bib@uab.cat  :: Metadata license:
Working with